Dechra Wins FDA Approval for Canine CosACTHen®
OVERLAND PARK, Kan., May 19, 2026 Dechra has announced that the U.S. Food and Drug Administration (FDA) approved CosACTHen®...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
OVERLAND PARK, Kan., May 19, 2026 Dechra has announced that the U.S. Food and Drug Administration (FDA) approved CosACTHen®...
Rahway, New Jersey, USA — February 25, 2026 The U.S. Food and Drug Administration (FDA) has approved NUMELVI™ (atinvicitinib...
PENSACOLA, Fla., Feb. 12, 2026 — The U.S. Food and Drug Administration has granted full approval to KBroVet (potassium...
Libourne, France — February 9, 2026: Ceva Animal Health, the world’s fifth-largest animal health company, has announced strategic leadership...
DULUTH, Ga., Feb. 5, 2026 — Boehringer Ingelheim Animal Health USA Inc. announced that the U.S. Food and Drug...
PARSIPPANY, N.J. — December 11, 2025 — Zoetis Inc., the world’s leading animal health company, announced that its Board...
